This study was done in Carlsbad, California at one of Immunovative Therapies, Ltd.'s sister facilities. Dr. Michael Har-Noy noted that forty-two patients with different tumor types were enrolled. All patients had been previously treated with large amounts of radiation and/or chemotherapy and were expected to live only 60 days or less. The average age of the patients was 61 years; 90% had previous surgery, 45% had previous radiation, and all had previous chemotherapy. The cancer cell types were: 14 breast, three gallbladder, seven colorectal, three ovarian, three squamous cell, two sarcoma, two pancreas, two esophageal, two lung, two prostate, and one bladder. These severely ill subjects averaged 22.2 metastatic lesions and had an average ECOG (Eastern Cooperative Oncology Group) score of 2.2, indicating grave disability.
Dr. Michael Har-Noy indicated that the study group as a whole suffered few side effects from AlloStimTM. The most frequently encountered side effect was a flu-like condition that appeared within the first few days after treatment.
The mean survival of the study patients, says Dr. Michael Har-Noy, was 163 days – almost three times the predicted survival in untreated patients with similar tumors. Amazingly, 20% of the study group was still in remission one full year after treatment! Some patients lived for years after the trial's conclusion. This author is unaware of the exact longevity of all patients, but in general these survival statistics are far superior to anything that has yet been published.
Dr. Michael Har-Noy will soon publish these study results in a peer-reviewed. He says that these results must be viewed with caution, as this was only a preliminary, uncontrolled trial. He will soon undertake a Phase II/III, randomized double-blind controlled trial of AlloStimTM in patients with metastatic colon cancer.